Grant: Master's Award: Canada Graduate Scholarships
University of Alberta
$17,500.00
Host Cell Signalling Mediates Respiratory Syncytial Virus and Bacterial Pneumonias
FY 2022-23
Summary
Respiratory Syncytial Virus (RSV) is the leading cause of infant hospitalizations worldwide. When infants and seniors are weakened by RSV infection, they are at risk for secondary pneumococcal pneumonia infections. These secondary infections are often caused by the bacteria Streptococcus pneumoniae. Co-infections of RSV and Streptococcus pneumoniae contribute to a significant number of hospitalizations and deaths in at-risk populations, despite the pneumococcal vaccine. There is no vaccine for RSV, and only one preventative treatment, therefore, there is a need to better understand these co-infections in order to develop new antiviral treatments. Our group has found previously that RSV can take advantage of the antiviral immune response to enhance its replication. This effect may be exacerbated during co-infections, leading to an increase in severity of symptoms. My project will elucidate the precise immune signalling molecules that are involved in amplifying RSV infections and co-infections. The molecules I identify could serve as novel drug targets to reduce the burden of RSV and pneumococcal co-infections.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
486320
Name
Granoski Madison J
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Host Cell Signalling Mediates Respiratory Syncytial Virus and Bacterial Pneumonias
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antivirals; Immunology; Kinase; Microbiology; Pathogenesis; Pattern Recognition Receptors; Pneumonia; Respiratory Syncytial Virus; Streptococcus Pneumoniae; Virology
Abstract
Respiratory Syncytial Virus (RSV) is the leading cause of infant hospitalizations worldwide. When infants and seniors are weakened by RSV infection, they are at risk for secondary pneumococcal pneumonia infections. These secondary infections are often caused by the bacteria Streptococcus pneumoniae. Co-infections of RSV and Streptococcus pneumoniae contribute to a significant number of hospitalizations and deaths in at-risk populations, despite the pneumococcal vaccine. There is no vaccine for RSV, and only one preventative treatment, therefore, there is a need to better understand these co-infections in order to develop new antiviral treatments. Our group has found previously that RSV can take advantage of the antiviral immune response to enhance its replication. This effect may be exacerbated during co-infections, leading to an increase in severity of symptoms. My project will elucidate the precise immune signalling molecules that are involved in amplifying RSV infections and co-infections. The molecules I identify could serve as novel drug targets to reduce the burden of RSV and pneumococcal co-infections.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Granoski, Madison J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~